Advertisement: Mogrify
RealVNC mid banner careers
Advertisement: Cambridge Network
Mid banner advertisement: BDO
Barr Ellison Solicitors – commercial property
ARM Innovation Hub
Advertisement: Bradfield Centre mid
RealVNC mid-banner general
Advertisement EY mid banner
Advertisement: RSM
15 August, 2019 - 20:18 By Tony Quested

Cambridge food supplement company to raise fresh growth capital

Cambridge startup FutureYou, a science-backed online food supplement company, has strengthened its management team on the back of dramatic and sustained growth and is raising growth capital. FutureYou is looking to raise between £2m and £5m.

The company has appointed its sixth member to the management team after increasing direct-to-consumer sales more than twenty-five fold over the past four years.

Expertise across the management team comes from blue-chip companies such as Abcam plc, Deloitte UK, Congenica and Whitbread plc.

Led by Adam Cleevely, FutureYou has enjoyed a remarkable record of growth, with direct sales increasing from £140,000 to over £4 million and headcount that has gone from four to 34 since 2016; the business recently gained its 100,000th customer.

FutureYou launched in 2016 as a patented range of science-backed supplements proven in multiple clinical studies. The original company known as Cambridge Nutraceuticals, was founded in 2012 under different management. 

CEO Cleevely joined in May 2015. At that time there were four employees including him. The company has over 100,000 customers with a goal of 250,000 by the end of 2020.

FutureYou currently sells directly to the consumer in the UK and has a 9.5 rating on TrustPilot thanks to its customer care team.

It pulled out of retail in 2016 to focus on online sales but will consider the right partnership in the future. Flagship products include Turmeric+ and Ateronon Heart (the ‘tomato pill’).

The company has close ties with Cambridge University and Addenbrooke’s Hospital and works with other leading research institutions. 

Product development is supported by a high-profile medical board including, among others, Professor Alf Lindberg, former head of R & D at Wyeth and Aventis and former member of the Nobel Committee and Secretary of the Medical Prize; Dr Nicholas Shenker, a consultant rheumatologist and expert in chronic pain syndromes at Addenbrooke’s Hospital; Peter Kirkpatrick, a leading Cambridge University vascular neurosurgeon and Michael Heinrich, head of University College London’s centre for Pharmacognosy and Phytotherapy.

Newsletter Subscription

Stay informed of the latest news and features